Archon is a biotechnology firm that creates computationally engineered proteins to unleash potent therapeutic targets beyond the grasp of current methods and improve disease management.
Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
Insamo is a biotechnology company focused on the discovery and development of membrane-permeable and orally available cyclic peptides, which possess antibody-like binding affinity. Utilizing an automated platform that integrates molecular biology and parallel synthetic chemistry, Insamo aims to rapidly identify preclinical candidates with favorable pharmacological properties. This innovative approach enables the potential replacement of traditional injected or infused biologics with more accessible oral formulations, thereby enhancing patient care. The company's automated design, synthesis, and testing processes allow for unprecedented scalability in the discovery of these therapeutic compounds.
Parse Biosciences is a biotechnology startup based in Seattle, Washington, that specializes in single-cell analysis. Founded in 2018 and rebranded from Split Biosciences in 2020, the company has developed innovative single-cell sequencing kit solutions that utilize combinatorial cDNA barcoding. This technology allows researchers to conduct experiments without the need for complex and costly microfluidic instruments. It also enables the fixation, freezing, and storage of samples, which separates sample extraction from downstream library preparation steps. As a result, researchers can analyze fixed samples collected on different dates in a single experiment, enhancing control over sample handling and minimizing errors. Additionally, Parse Biosciences’ technology improves gene detection in individual cells while reducing common confounding artifacts in single-cell sequencing, making it a valuable resource for researchers in the field.
Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
Monod Bio is a life sciences company based in Seattle, Washington, focused on developing innovative biosensors for detecting proteins, toxins, antibodies, and other analytes. Founded in 2021, the company has created a biosensor platform that integrates binding, transduction, and amplification processes in a single step, allowing for the rapid and sensitive detection of a diverse array of target molecules. By leveraging recent advancements in computational protein engineering, Monod Bio has designed highly modular bio-sensing nanoswitches that facilitate cost-effective analytical assays. This technology aims to enhance the capabilities of the healthcare industry in biotechnology and medicine.
Terray Therapeutics is a biotechnology company based in Pasadena, California, founded in 2018. The company specializes in developing innovative treatments for complex human diseases by integrating experimentation and computation to enhance small molecule drug discovery. Terray's unique platform employs ultra-dense microarray technology alongside artificial intelligence and synthetic chemistry to generate extensive and precise chemical datasets. This allows for a rapid design-make-test-analyze cycle, facilitating efficient exploration of chemical space and mapping biochemical interactions between small molecules and disease causes. By utilizing automation and machine learning, Terray addresses significant therapeutic challenges, ultimately guiding the next cycles of drug design and experimentation.
HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines. HilleVax was founded in 2021 and was headquartered in Boston, Massachusetts.
Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
Inspire is a patient engagement platform founded in 2005 and headquartered in Arlington, Virginia. The company connects patients and caregivers through a secure, permission-based online website and mobile application. This platform allows members to share and compare their health journeys, fostering a supportive community that enhances the understanding of patient experiences. Inspire's approach facilitates the integration of patient-connected real-world data into pharmaceutical research and product development, ultimately driving breakthroughs in healthcare. By focusing on the patient journey, Inspire aims to advance patient support and contribute to the pharmaceutical industry's innovations.
Elegen is a biotechnology company founded in 2017, focused on developing microfluidic technology to advance synthetic biology. Led by Dr. Matthew Hill, Elegen aims to revolutionize the field by engineering entire genomes and creating innovative DNA synthesizers. Their technology is designed to enhance the speed and efficiency of DNA sequence testing, thereby facilitating significant progress in biomedical research and healthcare applications. Through these efforts, Elegen seeks to contribute to the rapid development of solutions that address various challenges in the life sciences sector.
Athira Pharma, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing small molecules aimed at restoring neuronal health and addressing neurodegenerative diseases. The company's lead candidate, ATH-1017, is a small hepatocyte growth factor/MET activator designed to penetrate the blood-brain barrier and is currently undergoing various clinical trials for the treatment of Alzheimer's and Parkinson's diseases. Additionally, Athira is advancing other candidates, including ATH-1019, which is in preclinical development for depression, and ATH-1018, aimed at treating peripheral neuropathy. Founded in 2011 and originally named M3 Biotechnology, Athira Pharma changed its name in April 2019 to reflect its commitment to innovative therapies that positively impact individuals affected by brain disorders.
Kriya Therapeutics, Inc. is a gene therapy company dedicated to designing and developing treatments for chronic diseases. Founded in 2019 and headquartered in Palo Alto, California, with an additional office in Durham, North Carolina, the company has established a fully integrated platform that consolidates the essential infrastructure and technology for creating, manufacturing, and developing gene therapies. Kriya Therapeutics employs a vector design platform that enhances its ability to undertake novel construct design, targeted sequence modification, and comprehensive data analysis. This approach aims to reduce immunogenicity and improve tissue specificity, ultimately enabling physicians to provide more effective therapeutic options for patients.
TwinStrand Biosciences specializes in advanced DNA sequencing technologies, significantly enhancing the accuracy of mutation detection beyond conventional methods. Their proprietary Duplex Sequencing technology enables the identification of mutations that are often undetectable by standard approaches, making it valuable in various fields such as oncology, infectious disease, organ transplantation, reproductive and genetic health, and forensics. The company is dedicated to improving diagnostic capabilities and advancing research through its innovative sequencing solutions. TwinStrand is also involved in biopharmaceutical development, focusing on the discovery and commercialization of biological drugs aimed at treating life-threatening diseases, particularly cancers. Their product pipeline includes recombinant protein-based prodrugs designed for activation by matrix metalloproteinases associated with solid tumors.
Andes develops an integrated microbial technology to help accelerate crop growth. Its technology is combined with artificial intelligence to develop its seeds while reducing input costs and environmental footprints and helps farmers to boost their agricultural output and income. Andes was founded in 2018 and is headquartered in Alameda, California.
Agerpoint, Inc. specializes in providing information management solutions tailored for growers of tree and vine crops, as well as insurers and investors. The company develops advanced technologies to digitize and analyze natural environments, utilizing artificial intelligence and high-performance computing. Through its GroveTracker platform, Agerpoint offers growers critical insights into their crop holdings, including statistical and photographic data on their orchards and vineyards. The company integrates data from various sources, such as drones and satellites, to create precise digital records that enhance decision-making across sectors like agriculture, forestry, and environmental conservation. Founded in 2012 and headquartered in Research Triangle Park, North Carolina, Agerpoint aims to improve the understanding of plants and forests while contributing to efforts against climate change.
NuProbe, Inc. is a genomics and molecular diagnostics company that focuses on noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in Shanghai, China, NuProbe has developed a platform that utilizes genetic toehold probes for quantitative PCR mutation detection. The company's innovative technology offers a Sample-In Answer-Out (SIAO) solution, which seamlessly integrates cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatic interpretation. This precision diagnostic technology is designed to facilitate the early detection of cancer and infectious diseases by accurately capturing disease signatures with high sensitivity and multiplexing capability, allowing healthcare professionals to initiate timely interventions for patients.
Variant Bio Inc. is a biotechnology company based in Seattle, Washington, that focuses on developing therapeutics through the study of human genetic diversity. Founded in 2018, the company identifies individuals and populations that exhibit extreme traits of medical significance, utilizing advanced sequencing technologies and analytic methods to uncover the genes and pathways associated with these traits. By leveraging insights from genetic research, Variant Bio aims to discover new therapeutic targets for conditions such as neurodegenerative, autoimmune, and cardiometabolic diseases. The company's innovative approach combines statistical genetics and machine learning, enhancing the potential for genomic drug discovery to address unmet medical needs.
A-Alpha Bio, Inc. is a biotechnology company based in Seattle, Washington, established in 2017. The company specializes in synthetic biology, offering a platform known as AlphaSeq, which assists pharmaceutical companies in the development of drugs that interact with multiple targets. A-Alpha Bio provides cell-based tools for high-throughput and quantitative measurements of protein interactions, facilitating target discovery, library screening, and preclinical drug characterization. Its proprietary technology enables the mapping of protein-protein interactions at a large scale, allowing for the identification and quantification of interactions among thousands of protein pairs simultaneously. By delivering detailed maps of these interactions, A-Alpha Bio helps researchers identify potential drug targets and understand disease mechanisms, thereby streamlining the therapeutic discovery process and improving the efficiency of drug development. The company comprises a team of experts in synthetic biology, structural biology, and next-generation sequencing, focused on overcoming challenges in the drug development pipeline.
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Buffalo Grove, Illinois, focused on developing and commercializing innovative treatments for gastrointestinal diseases. Established in 2018 and launched in 2019, the company is advancing its lead drug candidate, vonoprazan, a potassium-competitive acid blocker (P-CAB) that effectively inhibits acid secretion in the stomach. Vonoprazan is currently undergoing Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease and is also being studied in combination with antibiotics for the treatment of Helicobacter pylori infection. The company aims to address significant unmet medical needs in patients suffering from acid-related disorders and has assembled a team of experts in the gastrointestinal and pharmaceutical fields to drive its development efforts.
Checkerspot, Inc. is a biotechnology company based in Berkeley, California, established in 2016. The company specializes in creating performance materials derived from microalgae, focusing on sustainable and high-performance applications. Checkerspot employs advanced techniques in molecular foundry, chemistry, material science, and fabrication technology to develop innovative products, including polyurethanes and textile finish materials. By leveraging the power of biotechnology, Checkerspot aims to expand the range of molecular building blocks available for various industrial applications, providing industries with access to a new generation of sustainable materials.
Impact Vitals is a developer of medical technologies focused on enhancing patient outcomes through advanced monitoring solutions. The company specializes in vital sign monitoring technology that utilizes machine learning to analyze physiological data, offering early warnings of potential health issues. This innovative approach provides healthcare providers with critical insights that facilitate timely interventions, ultimately aiming to lower costs and improve overall patient care. By transforming basic vital signs into actionable information, Impact Vitals contributes to life-saving and life-changing healthcare solutions.
Phase Genomics, Inc. is a biotechnology company based in Seattle, Washington, founded in 2015. The company specializes in developing innovative technology for genome assembly and metagenome deconvolution, focusing on its ProxiMeta Hi-C platform. This platform empowers researchers in various fields, including agriculture, human health, and industrial biology, by enabling the cultivation-independent assembly of bacterial genomes. By exploiting the structure of DNA, Phase Genomics aims to provide scientists with the most complete and accurate genomes and metagenomes possible, facilitating transformative discoveries and advancements in their respective areas of study.
Azitra is a clinical-stage medical dermatology company that leverages extensive scientific knowledge about the skin microbiome to discover and develop novel products for the treatment of adverse skin conditions and diseases.The Company’s technology platform, developed in collaboration with scientists at Yale University and the Jackson Laboratory, is based on a proprietary strain of the natural commensal bacteria Staphylococcus epidermidis.
Sana Biotechnology is a biotechnology company based in Seattle, Washington, with additional offices in South San Francisco, California, and Cambridge, Massachusetts. Founded in 2018, the company specializes in developing engineered cells as medicines to treat a variety of diseases. Sana Biotechnology focuses on reprogramming cells in the body and replacing damaged cells and tissues, leveraging recent scientific advancements to create new therapeutic options. The company's research spans multiple therapeutic areas with significant unmet needs, including oncology, diabetes, B-cell-mediated autoimmune disorders, and central nervous system conditions. Its pipeline includes various product candidates aimed at addressing these challenges through innovative cell engineering programs.
Parse Biosciences is a biotechnology startup based in Seattle, Washington, that specializes in single-cell analysis. Founded in 2018 and rebranded from Split Biosciences in 2020, the company has developed innovative single-cell sequencing kit solutions that utilize combinatorial cDNA barcoding. This technology allows researchers to conduct experiments without the need for complex and costly microfluidic instruments. It also enables the fixation, freezing, and storage of samples, which separates sample extraction from downstream library preparation steps. As a result, researchers can analyze fixed samples collected on different dates in a single experiment, enhancing control over sample handling and minimizing errors. Additionally, Parse Biosciences’ technology improves gene detection in individual cells while reducing common confounding artifacts in single-cell sequencing, making it a valuable resource for researchers in the field.
Lyell Immunopharma is a clinical-stage company focused on developing innovative T cell therapies for patients with solid tumors. The company aims to overcome major challenges in adoptive T cell therapy, such as T cell exhaustion and the loss of durable stemness, which affects the efficacy of treatment. To achieve this, Lyell employs proprietary ex vivo genetic and epigenetic reprogramming technologies, known as Gen-R and Epi-R, to enhance T cell functionality. The company's product pipeline includes several candidates, such as LYL797, LYL119, and LYL845, which are designed to provide improved and lasting therapeutic outcomes for patients.
Checkerspot, Inc. is a biotechnology company based in Berkeley, California, established in 2016. The company specializes in creating performance materials derived from microalgae, focusing on sustainable and high-performance applications. Checkerspot employs advanced techniques in molecular foundry, chemistry, material science, and fabrication technology to develop innovative products, including polyurethanes and textile finish materials. By leveraging the power of biotechnology, Checkerspot aims to expand the range of molecular building blocks available for various industrial applications, providing industries with access to a new generation of sustainable materials.
Avail Medsystems, Inc. is a digital healthcare company that develops a platform designed to remotely connect healthcare experts with practitioners. The company's integrated audio/visual hardware and software system facilitates procedural support, observation, and clinical education services, allowing healthcare professionals to collaborate effectively. By enabling real-time access to clinical expertise, Avail aims to eliminate physical, economic, and logistical barriers in the healthcare industry. This approach promotes innovation and enhances the adoption of medical tools and techniques, ultimately improving patient care. Founded in 2017 and based in Palo Alto, California, Avail Medsystems was previously known as Nurep, Inc. and underwent a name change in March 2018.
Neoleukin Therapeutics is a biopharmaceutical company based in Seattle, Washington, focused on developing immunotherapies for cancer, inflammation, and autoimmune disorders through innovative protein design technology. The company's primary product candidate, NL-201, is a de novo protein engineered to mimic the therapeutic effects of cytokines IL-2 and IL-15, targeting various cancers such as renal cell carcinoma and melanoma. Founded in 2003 and emerging from the University of Washington's Institute for Protein Design in 2019, Neoleukin utilizes advanced computational methods to create custom-designed proteins that offer enhanced pharmaceutical properties compared to natural proteins, aiming to provide superior therapeutic benefits for serious diseases.
Forterra is a non-profit organization that supports the Pacific Northwest and its wild mountains, rich ecosystems, farmland, small towns, and thriving cities.
PvP Biologics is developing an oral enzyme for the treatment of celiac disease. Our mission is to develop a highly-effective therapeutic product to reduce the burden of living with this disease. Towards this end, we are advancing a product candidate designed to break down the immuno-reactive parts of gluten in the stomach and thereby avoid the painful symptoms and damage done in the small intestine from accidental gluten ingestion.
TwinStrand Biosciences specializes in advanced DNA sequencing technologies, significantly enhancing the accuracy of mutation detection beyond conventional methods. Their proprietary Duplex Sequencing technology enables the identification of mutations that are often undetectable by standard approaches, making it valuable in various fields such as oncology, infectious disease, organ transplantation, reproductive and genetic health, and forensics. The company is dedicated to improving diagnostic capabilities and advancing research through its innovative sequencing solutions. TwinStrand is also involved in biopharmaceutical development, focusing on the discovery and commercialization of biological drugs aimed at treating life-threatening diseases, particularly cancers. Their product pipeline includes recombinant protein-based prodrugs designed for activation by matrix metalloproteinases associated with solid tumors.
SiDx is a health services provider based in Seattle, Washington, focused on modernizing blood group testing to enhance patient care and reduce costs. Founded in 2017, the company has developed a medical device that utilizes micro-sensors on a silicon chip, which are interrogated by laser technology to detect reactivity to various compounds. This innovative diagnostic platform allows healthcare providers to obtain test results during patient visits, thereby expediting the decision-making process and improving overall efficiency in medical testing.
Illumio, Inc. is a cybersecurity company based in Sunnyvale, California, founded in 2012. It specializes in cloud-based security solutions designed to protect organizations from cyber threats and enhance operational resilience. The company's core offering is the Adaptive Security Platform, which includes tools for data center and cloud traffic security. Key components of this platform are the Illumination application traffic mapping tool, the Enforcement application nano-segmentation solution, and SecureConnect for data protection. Illumio's approach centers on Zero Trust principles, helping organizations visualize traffic flows and implement segmentation policies that limit lateral movement within multi-cloud and hybrid infrastructures. This capability is essential for safeguarding critical resources and preventing the spread of cyber attacks. Illumio serves a diverse clientele, including notable companies such as Plantronics, Yahoo, Creative Artists Agency, and NTT Innovation Institute, Inc.
Rocket Pharmaceuticals is a biotechnology company dedicated to developing gene therapies aimed at treating rare pediatric diseases. The company's primary focus is on its lead program, a lentiviral-based gene therapy for Fanconi Anemia, a genetic disorder that leads to bone marrow failure. In addition to this, Rocket is advancing therapies for several other conditions, including Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-I, and Infantile Malignant Osteopetrosis, all of which are currently in various stages of clinical and preclinical trials. The company is also engaged in an adeno-associated virus program targeting Danon disease, a serious multi-organ disorder. Rocket Pharmaceuticals collaborates with various academic and research institutions, enhancing its research capabilities and expanding its therapeutic portfolio. The company is based in New York, New York.
Water1st International is a non-profit organization that provides and supports piped water systems and toilets projects for the world’s poorest communities that improve health, create opportunity, and break the cycle of extreme poverty.
Thorn (previously DNA Foundation and the Demi & Ashton Foundation) drives technology innovation to fight the sexual exploitation of children. They partner across the tech industry, government and NGOs and leverage technology to combat predatory behavior, rescue victims, and protect vulnerable children.
PoliarisProject is a humanitarian organization that aims to combat human trafficking and modern-day slavery. The organization operates hotlines, policy advocacy programs, client services, advisory services, strategic initiatives, data analysis programs, and global programs to achieve its mission. PolarisProject is based in Washington, D.C.
Amplio offers technology that overcomes barriers like low literacy, local languages, lack of electricity or internet, and traditional gender norms and biases that often limit access to information. With the battery-powered Amplio Talking Book, their partners can deliver hours of local language audio content.
Icosavax, Inc. is a biotechnology company based in Seattle, Washington, founded in 2017. The company specializes in developing vaccines using its innovative virus-like particle (VLP) technology platform, which allows for the multivalent display of complex viral antigens. This technology aims to provide broad and durable protection against various infectious diseases, with an initial focus on life-threatening respiratory illnesses. Icosavax's pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and SARS-CoV-2. The company is dedicated to advancing its VLP technology to discover, develop, and ultimately commercialize effective vaccines against these infectious diseases.
Potlatch Fund is a non-profit organization dedicated to youth development, community building, language preservation and education, and native arts. They also provide training around financial management, board governance, strategic planning, media management, and nonprofit development for past grantees.
Recursion Pharmaceuticals is a clinical-stage biotechnology company based in Salt Lake City, Utah, focused on transforming drug discovery through the integration of technology, particularly artificial intelligence, automation, and bioinformatics. Founded in 2013, the company utilizes a sophisticated drug discovery platform that includes various software solutions and robotic automation to enhance chemical compound selection, streamline experimental workflows, and evaluate drug efficacy. Key components of this platform involve tools for designing chemical compounds, planning complex experiments, and analyzing data to understand drug interactions and biological responses. By creating one of the largest proprietary biological and chemical datasets, Recursion aims to uncover new biological insights and expedite the development of innovative treatments, ultimately improving patient outcomes.
98point6 Inc. is a Seattle-based company that offers primary care services through its mobile application in the United States. Founded in 2015, it provides an on-demand, virtual primary care solution that allows board-certified physicians to deliver personalized consultation, diagnosis, and treatment for both acute and chronic illnesses. Utilizing a text-based platform, the service enables patients to communicate with healthcare providers anytime and anywhere, facilitating private consultations, diagnosing conditions, outlining care options, and managing prescriptions and lab tests. By leveraging technology, 98point6 aims to make healthcare more accessible and cost-effective, allowing physicians to focus more on patient care.
Magic Leap is an augmented reality company based in the United States that specializes in developing innovative hardware and software to enhance user interaction with digital devices. Its proprietary wearable technology allows users to experience augmented reality in a visually immersive manner. By leveraging dynamic-image computing and stereoscopic 3D technology, Magic Leap creates lifelike images that blend seamlessly into the real world, enhancing the way users visualize data and access digital content. The company's approach aims to bridge the gap between digital and physical experiences, enabling a unique and engaging interaction with technology through its advanced visual output capabilities.
Uterish operates as an online platform to connect activists, sell feminist apparel, publish an informative monthly newsletter, produce and curate opinionated blog posts, and support Planned Parenthood and the right to bodily autonomy.
Earth Economics identifies and quantifies those benefits to ensure they are included in the decision-making process at all levels.
GIRC&D is a community-based organization focused on the prudent use of natural and human resources. Originally sponsored by the U.S. Department of Agriculture and initially administered by the Natural Resources Conservation Service—a federal agency—we are now locally managed. The organization provides many avenues for worthy projects to succeed. Some projects that GIRC&D hosts are finite, but leave a lasting impact. Others become entities and nonprofit organizations on their own. Seven committees outreach to the community; one committee functions internally.
BROTMAN BATY INSTITUTE focuses on basic and applied research in genomics, bioinformatics, and data science to diagnose and cure disease. The Institute was founded in 2017 by philanthropic sponsors Jeff and Susan Brotman, and Dan and Pam Baty in collaboration with UW Medicine, The Fred Hutchinson Cancer Research Center, and Seattle Children’s. The Institute led by Dr. Jay Shendure was formed to accelerate both the basic sciences of precision medicine and the delivery of benefits to patients. The Institute organizes world-renowned investigators in genomics, bioinformatics and data science to share centralized platforms of advanced technologies and equipment in a uniquely collaborative manner. The Institute's aim is to develop insights and knowledge that will more precisely diagnose and treat people with cancer, rare childhood diseases, Alzheimer’s, and other conditions.
AgeneBio, Inc. is a neuroscience pharmaceutical company founded in 2008 by Dr. Michela Gallagher, focused on developing therapeutic products for Alzheimer's disease, dementia, and other memory disorders. The company's primary targets include Amnestic Mild Cognitive Impairment (aMCI) and Alzheimer's disease (AD). AgeneBio aims to create innovative therapeutics that prevent neurodegeneration and preserve cognitive function in patients at risk for neurological and psychiatric conditions. By addressing the symptomatic pre-dementia stage of Alzheimer's disease and other related disorders, AgeneBio seeks to provide effective treatments for individuals facing these challenging health issues. The company is headquartered in Indianapolis, Indiana, and engages in global research and development efforts through various partnerships.
TRACON Pharmaceuticals is a clinical-stage biopharmaceutical company based in San Diego, California, specializing in the development and commercialization of targeted therapies for cancer and wet age-related macular degeneration (AMD). Its lead product, envafolimab, is a PD-L1 single-domain antibody under investigation for soft tissue sarcoma, while other clinical candidates include TRC102, a small molecule in Phase II trials for lung cancer, and TJ004309, a CD73 antibody in Phase I development for advanced solid tumors. TRACON's development pipeline also features TRC253, which is being studied for metastatic castration-resistant prostate cancer. The company employs a capital-efficient, CRO-independent product development platform and actively seeks partnerships with companies outside the U.S. for regulatory and clinical development, as well as commercialization in the U.S. TRACON was founded in 2004 and was previously known as Lexington Pharmaceuticals until its rebranding in 2005.
Adaptimmune is a clinical-stage biopharmaceutical company based in Abingdon, United Kingdom, established in 2007. The company specializes in the development of T cell therapies aimed at treating cancer, human immunodeficiency virus, and infectious diseases. Adaptimmune employs a proprietary platform to identify cancer targets, genetically engineer T-cell receptors, and produce therapeutic candidates for patient administration. Its key programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell therapy, and CD70, among others, focusing primarily on solid tumors. By utilizing affinity T cell receptor proteins, Adaptimmune enhances the ability of patient T cells to target and destroy cancerous or infected cells.
The mission of the University of Washington Institute for Protein Design is to design a new world of proteins to address 21st century challenges in medicine, energy and technology. The Institute for Protein Design was established in 2012, and is building on strengths within the University of Washington and Seattle more generally. Protein design requires high-level expertise and talent in computing and software, biochemistry, genome sciences, biological structure, pharmacology, immunology and other basic science disciplines, as well as clinical medicine. They are marshaling deep institutional strengths in our faculty, scientific staff, postdoctoral fellows and graduate students, their partners from collaborating institutions, innovator networks, and from the computer and biotechnology industries — bringing extraordinary expertise to bear on a singular focus to advance the potential of protein design. Over the past 16 years, UW researchers have made significant progress in protein design and protein structure prediction, developing the world leading Rosetta software. During this period, UW scientists have developed methods for designing proteins with a wide range of new functions, including catalysts for chemical reactions, HIV and RSV vaccine candidates, and flu virus inhibitors. The IPD integrates these strengths in protein design with Seattle-area expertise in biochemistry, engineering, computer science and medicine, and leverages the exceptional Seattle strength in the software industry.
Landesa is a charitable organization founded in 1967 and based in Seattle, Washington, dedicated to helping impoverished individuals gain legal control over their land. Formerly known as the Center for Women's Land Rights, the organization rebranded in 2010. Landesa collaborates with governments, businesses, and local organizations to secure land rights for vulnerable populations. By ensuring that families have safe land rights, Landesa enables them to invest in their properties, leading to improved agricultural yields and benefits such as enhanced nutrition, health, education, resilience, and overall opportunities for future generations.
Washington Environmental Council is a non-profit organization. To advocate for environmental progress and justice through actions that mobilize the public, elect champions for the environment. They builds power for the environmental movement through community organizing, mobilizing people to speak up on issues as well as attend hearings and other civic engagement opportunities. They also work to educate and train civic activists and support youth-led activists.
Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.
Private Equity Round in 2011
Puma Biotechnology, Inc., is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB-272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2 positive metastatic breast cancer.
OCEAN FUTURES SOCIETY works to explore our global ocean, inspiring and educating people throughout the world to act responsibly for its protection, documenting the critical connection between humanity and nature, and celebrating the ocean's vital importance to the survival of all life on our planet.
Amara is an individual and family services organization that drives systemic change, promotes healing, racial, and LGBTQIA+ equity, by offering programs and services to families engaged in foster care, and to adoptees and families, post-adoption.
Plymouth Housing offers permanent homes and support services. They provide adults experiencing homelessness with opportunities to stabilise and improve their lives. They are preserving, developing, and operating safe, supportive housing.
Institute for Stem Cell and Regenerative Medicine (ISCRM) was founded in 2006 at the University of Washington by Tony Blau, Randy Moon, and Chuck Murry. The Institute is working to transform therapies for heart failure, neurodegenerative diseases including Parkinson’s and Alzheimer’s, muscular dystrophy, cancer, diabetes, hearing loss, and retinal, kidney, and liver diseases. Our scientists are conducting research using multiple approaches including pluripotent stem cell technology, gene therapy and precision medicine with the goal of developing novel therapies for diseases where there are few treatments at present.
Imagine a world where people are healthy. There would be less poverty and fewer orphans. There would be stronger economies. There would be hope.Seattle Biomedical Research Institute (Seattle BioMed) was founded at a time when infectious disease research in the U.S. was rare. Our founder had a vision to create a place where the brightest scientists could come together and generate new knowledge and develop innovative solutions to ultimately combat the world’s deadliest diseases. Today that vision is reality. 360 people strong, we're an internationally renowned, non-profit research Institute striving every day to eliminate the world's most devastating infectious disease.
R Baby is the first and only foundation focused on making sure every emergency room is prepared to give babies and children lifesaving care. The organization focuses on the delivery optimal pediatric emergency training, research, treatment, and equipment.
Ashesi University is a coeducational institution whose goal is to educate African leaders of exceptional integrity and professional ability. By raising the bar for higher education in Ghana we aim to make a significant contribution towards a renaissance in Africa. The university, which began instruction in March 2002 with a pioneer class of 30 students, has quickly gained a reputation for innovation and quality education in Ghana. Ashesi is the first university in Ghana to adopt and blend the Liberal Arts method of education with majors in Computer Science, Management Information Systems and Business Administration. The university is an independent, private, not-for-profit institution. Our mission is to educate a new generation of ethical, entrepreneurial leaders in Africa; to cultivate within our students the critical thinking skills, the concern for others, and the courage it will take to transform their continent.
Math for America is a charitable organization. They offer participation in a professional community, which is critical to sustaining teachers in their careers and attending, designing, and leading courses. It also developed a network of master teacher programs.
The Center for Constitutional Rights is dedicated to advancing and protecting the rights guaranteed by the United States Constitution and the Universal Declaration of Human Rights. Founded in 1966 by attorneys who represented civil rights movements in the South, CCR is a non-profit legal and educational organization committed to the creative use of law as a positive force for social change.
The Canada Green Building Council is involved in the design, construction, and operation of green buildings. They provide the products and services the building sector needs to construct and manage buildings that are easier on resources, healthier for people, and more cost-effective. Their government advocacy efforts help shape the government programs and policies that need to accelerate green buildings, lower carbon emissions, and create equitable communities.
Queens College offers a rigorous education in the liberal arts and sciences under the guidance of a faculty dedicated to both teaching and research. Students graduate with the ability to think critically, address complex problems, explore various cultures, and use modern technologies and information resources.
Pomona College offers students the experience of a liberal arts college and the breadth of resources associated with major universities. In the desert landscape that was inland Southern California in 1887, it took the audacity to imagine a college in a garden. Yet far from the ivied halls of the Northeast, Pomona's founders envisioned "a college of the New England type," with small classes, close relationships between students and faculty, and a green jewel of a campus. From that beginning, Pomona has grown to be one of the nation's premier liberal arts colleges. Located in Claremont, California, on a campus where ivy and palm trees coexist under habitually sunny skies, Pomona offers an environment for intellectual development and personal growth that is second to none. Today, Pomona offers its approximately 1,500 students-evenly divided between men and women-a comprehensive curriculum in the arts, humanities, social sciences, and natural sciences. With a student-faculty ratio of 8 to 1, students have the opportunity to work closely and collaboratively with professors who are also top scholars in their fields. Students and faculty challenge each other in laboratories, classrooms, and co-curricular activities, and everyone benefits from the energy generated by such an assemblage of sharp and eager minds. Friendships forged among Pomona faculty and students frequently endure far beyond the four years of college. Few institutions can match Pomona's ability to combine such intimate qualities as an average class size of 15 with such large-scale resources as a two-million-volume library. As the founding member of The Claremont Colleges, a unique consortium of seven independent institutions on adjoining campuses, Pomona offers its students the personal experience of a small, academically superb liberal arts college and the breadth of resources normally associated with major universities. Students challenge and learn from one another not only in the classroom but also in daily life. On-campus housing is guaranteed, and few students choose to live anywhere else. The extraordinary ethnic and social diversity of its student body gives Pomona a broader mix of backgrounds than just about any comparable educational institution. Their location-within an hour of the Pacific Ocean, the Mojave Desert, the San Gabriel Mountains, and the city of Los Angeles informs and shapes daily life at the College. There aren't many places in the world where you can ski in the morning, play on the beach in the afternoon, and take in a major league baseball game or an opera at night (not to mention the simple joy of wearing flip-flops in the middle of February). But beyond the recreational and cultural possibilities, our location also adds another dimension to the learning experience, with unequaled opportunities for field study, community involvement, and internships.
Northwest Harvest distributes food to a network of more than 370 food banks, meal programs, and high-need schools throughout Washington State.
Brady works across Congress, courts, and communities to end gun violence.
As the political leader of the pro-choice movement, NARAL Pro-Choice America marshals its resources—the power of people, policy expertise, and political acumen—to make a difference in the lives of women and their families.With more than one million members and supporters, NARAL Pro-Choice America uses the political process to guarantee every woman the right to make personal decisions regarding the full range of reproductive choices, including preventing unintended pregnancy, bearing healthy children, and choosing legal abortion.We are working with the Obama administration and Congress to pursue commonsense solutions, like increasing access to family planning and sex education, and reversing President Bush's anti-choice legacy.
Pesticide Action Network North America is a pesticide and biotech corporation that creates a thriving food system. They grow food, placing the health and economic burdens of pesticide use on farmers, farmworkers, and rural communities. They link local and international consumers and labor into an international citizens action network.
PACIFIC WILDLIFE PROJECT is a humane organization specializing in the rescue and care of wildlife. PACIFIC WILDLIFE PROJECT was Founded in 1985 with the humane goal of wildlife protection and preservation through education, community outreach, and rescue and medical treatment of all wild species.
Galapagos Conservancy is dedicated exclusively to the long-term protection of nature. Galapagos Conservancy is committed to strengthening local institutions and to creating local capacity to ensure the long-term protection of the archipelago.
The Dian Fossey Gorilla Fund is a non-profit organization dedicated to gorilla conservation.